We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OPDP Warns Outlook Pharma Over ADHD Drug Advertisement
OPDP Warns Outlook Pharma Over ADHD Drug Advertisement
The FDA’s Office of Prescription Drug Promotion (OPDP) sent its first warning letter of the year to Outlook Pharmaceuticals of Cincinnati, Ohio over a sponsored link for its ADHD treatment ProCentra (dextroamphetamine sulfate).